HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83
HC Wainwright & Co. 維持對Apellis Pharmaceuticals的買入評級，將目標價下調至83美元
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $92 to $83.
HC Wainwright & Co. 分析師Douglas Tsao 維持apellis pharmaceuticals（納斯達克: APLS）的買入評級，將目標價從92美元降至83美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。